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http://www.biomedcentral.com/1471-2415/12/43RESEARCH ARTICLE Open AccessA comparison of the sensitivity of EQ-5D, SF-6D
and TTO utility values to changes in vision and
perceived visual function in patients with primary
open-angle glaucoma
Fiammetta Maria Bozzani1*, Yasmene Alavi1, Mireia Jofre-Bonet2 and Hannah Kuper1Abstract
Background: Economic viability of treatments for primary open-angle glaucoma (POAG) should be assessed
objectively to prioritise health care interventions. This study aims to identify the methods for eliciting utility values
(UVs) most sensitive to differences in visual field and visual functioning in patients with POAG. As a secondary
objective, the dimensions of generic health-related and vision-related quality of life most affected by progressive
vision loss will be identified.
Methods: A total of 132 POAG patients were recruited. Three sets of utility values (EuroQoL EQ-5D, Short Form
SF-6D, Time Trade Off) and a measure of perceived visual functioning from the National Eye Institute Visual
Function Questionnaire (VFQ-25) were elicited during face-to-face interviews. The sensitivity of UVs to differences in
the binocular visual field, visual acuity and visual functioning measures was analysed using non-parametric statistical
methods.
Results: Median utilities were similar across Integrated Visual Field score quartiles for EQ-5D (P = 0.08) whereas
SF-6D and Time-Trade-Off UVs significantly decreased (p = 0.01 and p = 0.001, respectively). The VFQ-25 score varied
across Integrated Visual Field and binocular visual acuity groups and was associated with all three UVs (P≤ 0.001);
most of its vision-specific sub-scales were associated with the vision markers. The most affected dimension was
driving. A relationship with vision markers was found for the physical component of SF-36 and not for any
dimension of EQ-5D.
Conclusions: The Time-Trade-Off was more sensitive than EQ-5D and SF-6D to changes in vision and visual
functioning associated with glaucoma progression but could not measure quality of life changes in the mildest
disease stages.
Keywords: Glaucoma, Quality of life, Utility values, Cost-utility analysisBackground
Glaucoma is the second leading cause of blindness
worldwide, representing 12.3% of the global burden [1].
Primary open-angle glaucoma (POAG) is the most wide-
spread form among Western populations; if untreated,
this chronic degenerative optic neuropathy induces pro-
gressive and irreversible loss of peripheral visual field* Correspondence: fiammetta.bozzani@lshtm.ac.uk
1London School of Hygiene and Tropical Medicine, Keppel Street, WC1E 7HT,
London, UK
Full list of author information is available at the end of the article
© 2012 Bozzani et al.; licensee BioMed Centra
Commons Attribution License (http://creativec
reproduction in any medium, provided the or(VF) with tunnel vision and, eventually, blindness.
POAG prevalence is 2% among adults (>40 yrs) in high-
income countries and is predicted to rise with popula-
tion ageing, in turn expanding demand for therapies [2].
As health care resources become constrained, the im-
portance of evaluating the economic viability of different
treatment options is increasing [3].
Interventions should be compared through cost-utility
analysis based on Quality-Adjusted Life-Years (QALYs),
a common metric of benefit whose components are life
expectancy and Utility Values (UVs) [4]. The latter is al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated with different health states, ranging between
0 (death) and 1 (perfect health) [3,5]. Accurate estimates
of changes in UVs for progressive stages of visual field
loss (VFL) are needed to calculate QALYs gained from
glaucoma interventions [6]. Elicitation methods should
therefore detect genuine changes in QOL from the very
early stages of POAG and beyond. These changes are
defined as the minimally important difference in score
(i.e. the smallest difference perceived by patients as
beneficial), which would call for implementing the
intervention in the absence of side effects and excessive
cost [7].
Different methods for measuring UVs in POAG
patients, including both direct and indirect utility elicit-
ation, have been described in the literature, showing
various strenghts of association with VFL [6,8-13]. High
frequencies of ceiling effects, which can lead to under-
estimating QOL changes, have been reported for UV
instruments among these studies [14]. In addition, the
insensitivity of standard UV elicitation methods, such as
the EuroQoL EQ-5D advocated by the National Institute
for Health and Clinical Excellence for use in economic
evaluations, has been criticised among ophthalmic and
non-ophthalmic populations [15,16]. To date, few eco-
nomic evaluations on glaucoma interventions have been
conducted, with a recent systematic review calling for
more research in light of the scarcity and poor quality of
existing economic evidence compared to the wealth of
new technologies to assess [17]. Similarly, there have
been limited investigations directly comparing the sensi-
tivity of different UV elicitation methods in POAG re-
search [12,18].
As for the aspects of daily living affected by POAG,
few studies currently describe stage-by-stage losses in
different QOL dimensions [6,8,19]. However, a consider-
able body of evidence gathered using the National Eye
Institute Visual Function Questionnaire (VFQ-25) indi-
cates that QOL decreases from the early stages of visual
field deterioration, with the most affected areas being
driving and outdoor mobility [6]. Concerns with activ-
ities requiring near vision only emerge when field dam-
age is severe enough to affect binocular central acuity
[20,21].
Thus, UVs used in cost-utility analysis for POAG
should be sensitive to QOL changes associated with dis-
ease progression, yet there is limited evidence on which
UV elicitation methods are most sensitive to these
changes. The study objective is to identify among 3
widely used methods (EQ-5D, Short Form SF-6D, Time-
Trade-Off ) the one most sensitive to changes in both
binocular VFL and visual functioning (measured using
the VFQ-25). In particular, the following psychometric
properties of the elicitation methods will be assessed:known-group differences (ability to discriminate among
patients on different levels of condition severity) and
convergent validity (extent to which the UVs correlate
with the visual functioning score) [22].
Methods
This paper is part of a wider study on QOL in glaucoma
patients. It follows an article recently published by Alavi
et al. (2011), aimed at developing an algorithm to calcu-
late UVs for POAG patients based on a combination of
visual acuity (VA), visual field and contrast sensitivity
tests [23]. Full details of study methods are published in
Alavi et al. (2011). Ethics approval was granted by Moor-
fields and Whittington Local Research Ethics Committee
and the London School of Hygiene & Tropical Medicine
Ethics Committee.
Design and sample
A sample of outpatients with POAG in one or both
eyes was recruited from Moorfields Eye Hospital (MEH,
London, UK). After identification through clinical
records, those who consented to participate undertook
questionnaires and visual tests at MEH on the day their
next scheduled consultation occurred.
For eligibility, patients had to be at least 18 years old,
English-speaking and free from conditions preventing
reliable visual testing and interviewing. Exclusion criteria
were eye surgery in the preceding 6 weeks and any ocu-
lar co-morbidities contributing to loss of vision.
Clinical measures of visual function
Binocular measures of VF were selected as more rele-
vant to perceived visual ability. Integrated Visual Field
(IVF) scores were used to measure binocular VF as they
are derived from routine monocular VF threshold tests
and have been demonstrated to predict self-reported
visual disabilities better than the Esterman test [24].
Monocular Humphrey 24–2 full threshold tests were
performed in both eyes (Humphrey Field Analyzer II,
model 730; Humphrey Instruments, Dublin, CA, USA).
The maximum sensitivity (dB) recorded between the 52
overlapping points of the right and left monocular fields
was used to generate a 52-point integrated (binocular)
VF. Points were then scored (<10 dB = 2; 10-19 dB= 1;
≥20 dB = 0) and values summed up to obtain individual
IVF scores ranging from 0 (>20 dB in all 52 points) to
104 (<10 dB in all 52 points), respectively the best and
worst binocular VF [24]. Only scores obtained through a
reliable VF test, as defined by published criteria, were
included in the analysis [25]. IVF scores were based on
the monocular VF for participants with (1) no perception
of light (NPL) in one eye, or (2) severe visual loss (mean
deviation≤−25 dB) in one eye in their most recent test,
and whose eyesight had deteriorated to the extent that
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104 was designated to those participants who had NPL/
severe visual loss in both eyes, such that a reliable VF
was unobtainable from either eye. Lacking a universally
recognised glaucoma staging system, IVF quartiles were
used as a measure of VFL severity.
Visual acuity, both monocular and binocular (VAB),
was assessed under standardised conditions using a
back-illuminated ETDRS logMAR chart (Lighthouse
International, New York, NY) read with the aid of the
participants’ habitual distance glasses at 4 meters, or 2/1
metres if the letters on the top line could not easily be
read at 4/2 metres, respectively. Patients unable to see
letters at 1 metre were assigned a value of 1.85 logMAR,
(counting fingers), or 2.3 logMAR (vision of hand move-
ments or less) [26].
Interviews and UV/perceived visual function
measurement
Questionnaires and visual tests were administered by the
same researcher (YA) at MEH. Information was col-
lected on age, glaucoma diagnosis, gender, ethnicity,
education, marital status, living arrangements, use of
topical medication, previous glaucoma surgical or laser
interventions and time since diagnosis. A depression
screener was also administered [27]. Socio-economic sta-
tus was recorded using the occupational-based UK five-
class National Statistics Socio-Economic Classification
System [28]. A trained counsellor was available to parti-
cipants upset by any part of the interview.
Utility measures: The present analysis employs 3 elicit-
ation methods. Two are multi-attribute utility classifica-
tion systems providing preferences associated with
generic health states (EQ-5D, SF-6D), while the Time-
Trade-Off (TTO) directly elicits preferences associated
with current visual state. The EQ-5D consists of five
questions on mobility, self-care, usual activities, pain/
discomfort and anxiety/depression, that can take one of
three responses representing different levels of problems
(none/moderate/extreme). Individual sets of answers are
scored according to the health state they represent and
converted to UVs [29]. The Medical Outcomes Study
Short Form Questionnaire (SF-36) contains 36 items
assessing 8 domains of daily living on a 0–100 scale,
yielding the norm-based physical and mental component
summary scores [30,31]. Six of the 8 dimensions can be
used to generate UVs (SF-6D) [32]. A two-part TTO
question widely used in ophthalmic research with
demonstrated validity and test-retest reliability was ap-
plied in this study [33-38]. Participants were first asked
how many more years they expected to live (Y), and
then to quantify how many of those years – if any- they
were willing to trade for perfect vision. The UVs were
calculated from the maximum number of years that theperson was willing to trade (Z) as follows: UV= (Y−Z)/
Y. Thus, the method elicits stated (rather than revealed)
preferences.
Perceived visual function measure: VFQ-25 comprises
25 questions used to calculate 12 sub-scales (one
assessing general health and the remainder targeting
vision-specific functioning) and one composite score
between 0 and 100 [39]. Lower scores indicate lower
quality of life.Data analysis
Data were double-entered on an Access-based database,
checked using EpiInfo™ Data Compare and analysed with
STATA v.11 (StataCorp LP, College Station, TX, USA).
As the main vision and QOL measures were not nor-
mally distributed, even after log transformation, a pre-
liminary investigation of the statistical association
between variables was performed using non-parametric
Spearman’s rank correlation coefficient. Differences
between the three sets of UVs were tested with the
Wilcoxon signed-rank test. Next, the distribution of
median UVs and QOL scores across IVF quartiles was
analysed graphically. Associations between (1) the vision
markers (IVF and VAB) and the UVs and (2) the vision
markers and the VFQ-25 composite score were tested
using the Kruskal-Wallis test, a non-parametric equi-
valent of ANOVA. Individual socio-demographic and
clinical characteristics were considered as potential con-
founders. As nonparametric tests do not allow to control
for confounding, their associations with the vision mar-
kers, the UVs and the VFQ-25 score were independently
tested. Individual sub-scales from EQ-5D, SF-36 and
VFQ-25 were analysed graphically and using Spearman’s
correlation coefficients to assess which dimensions of
generic and vision-specific QOL were most affected by
glaucoma-induced VFL.Results
The characteristics of the 132 patients recruited are
summarised in Table 1. Most patients (65%) had been
diagnosed with glaucoma over 10 years prior to the
study and nearly 70% had not undergone surgery. The
full range of IVF scores was represented, although their
distribution was skewed towards mild/moderate VFL
(median = 29, IQR: 7.5 - 58, range: 0 – 104). The IVF
quartiles were: 0–7 (Q1), 8–29 (Q2), 30–59 (Q3), 60–
104 (Q4). The VAB of most patients was within the nor-
mal range (median = 0.1, IQR: 0–0.3, range: -0.18 - 1.85).
None of the variables listed in Table 1 was simultan-
eously associated with ophthalmic and QOL measures,
thus ruling out major confounding and justifying the use
of unadjusted values. In particular, UVs did not change
with age, a priori considered an important potential
Table 1 Socio-demographic and clinical characteristics of
patients with POAG (n = 132)
N Mean (SD) or % Range
Socio-demographic
Gender
Female (%) 61 46.2%
Male (%) 71 53.8% -
Age, mean (SD) 132 71.8 (11.0) 27.6 - 93.5
Living conditions
Living alone (%) 49 37.1% -
Not living alone (%) 83 62.9%
Employment
Currently employed (%) 27 20.5% -
Retired (%) 105 79.5%
Clinical
Years since POAG diagnosis,
mean (SD)
128 14.3 (8.9) 0.28 - 40.6
Type of glaucoma*
High tension 115 87.1% -
Normal Tension 17 12.9%
Currently using
eye-drops (%)
Yes 122 92.4% -
No 10 7.6%
Failed depression
screener (%)
Yes 10 7.6% -
No 122 92.4%
Visual
IVF , mean (SD)** 124 33.6 (37.6) 0 - 104
Better-seeing eye VA
(logMAR), mean (SD)
132 0.3 (0.4) −0.2 - 2.3
VAB (logMAR), mean (SD) 132 0.2 (0.4) −0.18 - 1.85
Best-eye mean deviation,
mean (SD)
101 −11.5 (8.2) −29.6 – 1.10
Worse-eye mean deviation,
mean (SD)
122 −18.9 (8.2) −31.9 – 0.4
* High and normal tension glaucoma defined on the basis of intraocular
pressure (normal: 10–21 mm Hg; high: >21 mm Hg).
**Higher values represent increasing visual field loss. 8 patients were unable
to score a reliable VF test due to low vision (n = 124/132).
IVF = integrated visual field score.
VAB = binocular visual acuity.
Table 2 Summary of utility values and VFQ-25 scores
N Mean
(SD)
Median (IQR) Observed
range
Possible
range*
EQ-5D 131 0.8 (0.2) 0.8 (0.7 - 1.0) −0.1 - 1.0 −0.6 – 1.0
SF-6D 126 0.7 (0.1) 0.7 (0.6 - 0.9) 0.4 - 0.9 0.3 – 1.0
TTO 123 0.9 (0.2) 1.0 (0.8 - 1.0) 0.2 - 1.0 0 – 1.0
VFQ-25 132 72.9 (22.1) 81.1 (57.8 - 91.6) 17.1 - 99.4 0 – 100
* Higher values indicate better health.
EQ-5D =UVs derived using EuroQoL Index tool. UK population norms
(n = 1763) by age group are the following, mean (SD) 45–54: 0.85 (0.25); 55–64:
0.80 (0.26); 65–74: 0.78 (0.26); 75+: 0.73 (0.27) [52].
SF-6D =UVs derived from SF-36 using SF-6D algorithm [53].
TTO = time trade-off utility value.
VFQ-25 = 25-item national eye institute visual function questionnaire.
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for SF-6D; P = 0.48 for TTO).
Table 2 provides a summary of VFQ-25 composite
scores and UVs derived from EQ-5D, SF-6D and TTO.
Their frequency distributions were heavily skewed to-
wards higher values, especially for TTO, whereby 79/123
respondents reported UV= 1. The three questionnairesyielded significantly different UVs (P ≤ 0.001 for all tests),
those from TTO being the highest. Less than 1% of all
items were missing for both EQ-5D and SF-6D. Utilities
could not be assigned to patients who did not answer
one or more questions used in the calculation algorithm
(n = 6). As for TTO, a common reason for refusal was
inability to consider the question independently from re-
ligious beliefs (cited in 4/9 cases).Stage-dependent changes in visual functioning and QOL
The VFQ-25 composite score correlated well with IVF
(r =−0.67) and VAB (r =−0.71), and its median declined
across IVF and VAB quartiles (Figure 1; Kruskal-Wallis
P < 0.001). There was strong evidence of a relationship
between VFL and every VFQ-25 sub-scale (all P < 0.001),
except for general health (P = 0.10) and ocular pain
(P = 0.16). The same associations were found for VAB
(P < 0.001 for all tests but general health and ocular pain,
both P = 0.35). The graphical comparison shows different
patterns of change for different dimensions of visual
functioning. The driving and peripheral vision sub-scales
displayed the largest declines even among patients in the
early stages of POAG, with the median score for driving
ability equal to 0 in the 3rd and 4th quartiles. Apart from
general health and ocular pain, which did not vary, all
sub-scales displayed large differences in median scores
only in the 4th IVF quartile compared to the others.
Only the SF-36 sub-scales related to its physical com-
ponent were associated with VFL and VAB, (P = 0.03 and
P= 0.01, respectively; P = 0.4 and P= 0.92 for the psycho-
logical component). No EQ-5D dimension was asso-
ciated with VFL or VAB, except for ‘usual activities’
(P = 0.001).Sensitivity of UVs to differences in visual field
Table 3 reports the correlation coefficients between the
vision markers and the UVs. The TTO preferences for
visual states correlated much better with IVF and VAB
than preferences for generic health states. None of the
Figure 1 Median (IQR) VFQ-25 composite and subscales scores by IVF quartile.
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VFQ-25 composite score.
Figure 2 shows a declining trend in UVs from SF-6D
and TTO for increasing VFL, with patients in the 4th
quartile showing lower median UVs than those in the
first; the significant difference (P = 0.01 and p= 0.001, re-
spectively) was mainly driven by the lower utilitiesTable 3 Spearman’s rank correlation coefficients and
significance levels between VA, IVF and responses to
QOL questionnaires
IVF VAB
r P-value r P-value
EQ-5D −0.25 0.003 −0.19 0.03
SF-6D −0.29 0.001 −0.22 0.01
TTO −0.47 <0.001 −0.48 <0.001
VFQ-25 −0.67 <0.001 −0.71 <0.001
IVF = integrated visual field score.
VAB = binocular visual acuity.
EQ-5D =UVs derived using EuroQoL Index tool.
SF-6D =UVs derived from SF-36 using SF-6D algorithm [53].
TTO = time trade-off utility value.reported by patients in the 4th VFL quartile. Median UVs
from EQ-5D did not vary (P = 0.08) nor were signifi-
cantly different from population norms (Table 2). The
comparison of median UVs across VAB quartiles also
showed an association with SF-6D (P = 0.02) and TTO
(P < 0.001) but not EQ-5D (P = 0.17).Sensitivity of UVs to changes in visual functioning
As shown in Table 4, Spearman’s rank correlation coeffi-
cients indicate statistical dependence between the VFQ-
25 composite score and the UVs from EQ-5D, SF-6D
and, in particular, TTO.
All the individual VFQ-25 dimensions correlated well
with TTO (r≥ 0.50 and P < 0.001 for all tests) except for
general health and ocular pain. Correlations were instead
weak between UVs from EQ-5D and SF-6D and all sub-
scales other than general health. In fact, TTO was sensi-
tive to changes in the largest number of vision-specific
sub-scales, capturing up to 25% more of the impact of
vision loss on functionality dimensions such as driving
and social functioning (in terms of the difference
Figure 2 Median (IQR) of EQ-5D, SF-36 and TTO UVs by IVF quartile. Q-5D=UVs derived using EuroQoL tool. SF-6D=UVs derived from
SF-36 using SF-6D algorithm [53]. TTO= time trade-off utility value.
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and SF-6D.
Discussion
Although official guidelines on QALY estimates recom-
mend generic health-state valuations that reflect the pre-
ferences of the general population to improve the
comparability and generalisability of results, such valua-
tions may not detect changes in health status for someTable 4 Spearman’s rank correlation coefficients and
significance levels between utility values and VFQ-25
scores
VFQ-25 scores EQ-5D SF-6D TTO
r P-value r P-value r P-value
General health 0.56 <0.001 0.49 <0.001 0.12 0.226
General vision 0.27 0.002 0.24 0.004 0.45 <0.001
Ocular pain 0.42 <0.001 0.28 0.001 0.24 0.014
Near-vision activities 0.37 <0.001 0.42 <0.001 0.6 <0.001
Distance-vision activities 0.31 <0.001 0.41 <0.001 0.56 <0.001
Social functioning 0.24 0.007 0.36 <0.001 0.50 <0.001
Mental health 0.37 <0.001 0.44 <0.001 0.57 <0.001
Role difficulties 0.36 <0.001 0.48 <0.001 0.55 <0.001
Dependency 0.41 <0.001 0.48 <0.001 0.57 <0.001
Driving 0.24 0.018 0.21 0.057 0.46 <0.001
Colour perception 0.22 0.015 0.36 <0.001 0.45 <0.001
Peripheral vision 0.26 0.004 0.38 <0.001 0.45 <0.001
Composite score 0.38 <0.001 0.43 <0.001 0.60 <0.001
EQ-5D =UVs derived using EuroQoL Index tool.
SF-6D =UVs derived from SF-36 using SF-6D algorithm [53].
TTO = time trade-off utility value.
VFQ-25 = 25-item national eye institute visual function questionnaire.conditions [40]. The low sensitivity of generic instruments
can be attributed to the irrelevance of some of their ques-
tions to vision-related QOL. For instance, EQ-5D asks
about problems with mobility but these may not occur
until the very last stages of POAG, if at all. Moreover, the
three response options might not detect QOL changes of
a smaller magnitude. To address issues of poor sensitivity
and ceiling effects displayed by the original instrument, a
5-level version of EQ-5D was recently introduced, thus
potentially improving its performance at the milder end
of visual function loss [22,41]. Similar conclusions can be
drawn about the performance of SF-6D: it detects a min-
imally important difference in QOL, perceived by patients
as beneficial, that is different in absolute terms but pro-
portionally equivalent to that of EQ-5D [42]. Genuine dif-
ferences of a smaller magnitude are therefore undetected
by both instruments. Lack of specificity may compound
the problem as, for instance, generic measures may not
reflect glaucoma patients’ preference concerning both dis-
ease symptoms and avoidance of treatment side-effects.
Our findings on EQ-5D are in line with existing literature
showing no significant association between EQ-5D scales
and glaucoma severity [19,43]. Results in other chronic
conditions, ophthalmic and non- (including macular de-
generation, rheumatoid arthritis and asthma), indicate
that EQ-5D has limited disease-specific sensitivity [44-
46]. A complementary explanation has to do with the fact
that the frequency and intensity of negative thoughts has
an impact on responses to QOL questionnaires [47]. In
this sense, since generic tools do not require patients to
focus on the state of their vision, existing problems with
vision-related functioning might not be captured in their
score.
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changes of the TTO adapted to vision is consistent with
the question being specific to vision, and has also been
documented by Aspinall et al.. (2008), who observed de-
clining TTO utilities with increasing severity while EQ-
5D remained unaffected [8]. However, TTO has high
ceiling effects and does not decrease with deteriorating
vision and visual functioning in the earlier stages of dis-
ease (median UV= 1 for first 3 quartiles): preferences
may indeed not change until end-stage POAG, as
patients adapt to gradual peripheral vision loss, or the
elicitation methods may be inadequate. Ceiling effects
for generic utility scales are widely reported for ophthal-
mic conditions and in general population surveys
[48,49]. The high documented percentage of zero-
traders with TTO (UV= 1) may be explained with a
‘threshold of tolerability’ that should be reached before
patients are willing to sacrifice even a few days [50].
Similar findings with Standard Gamble utilities confirm
that glaucoma patients are willing to accept lower risks
in return for perfect health (UVs closer to 1) than
patients with other eye conditions such as refractive
error or diabetic retinopathy [51]. For the same patients,
utilities did decline once the anchor points were shifted
from death and perfect health to blindness and perfect
vision but the discrepancy between the two sets of UVs
remained largest with increasing disease severity [51].
EQ-5D was also appears to lack sensitivity to mild con-
ditions and small changes in health status [4].
Willingness to trade time was found predominantly
among patients with severe glaucoma, characterised by
poorer central VA; however, central VA might not de-
teriorate until later stages of POAG, leaving VFL as the
main determinant of early QOL changes. VFL affects a
selected number of functionality dimensions that might
not be encompassed within generic utility elicitation
methods: some of the reported associations between
functional ability and VFL were weaker than those with
VA [11]. Here, instead, all the associations found for
VAB and IVF were matched, thus confirming the rele-
vance of these findings for glaucoma patients, whose
vision loss is mainly peripheral. In line with existing
literature, we found that the VFQ-25 subscales showing
the lowest scores in POAG are driving, peripheral vision
and activities involving both near and distant vision
[20,21].
Our study has some limitations. Firstly, there are
significant differences in the TTO, EQ-5D and SF-6D
methods which limit their comparability. The TTO does
not value health states worse than death, and is anchored
differently (perfect vision/death) to the EQ-5D and
SF-6D (perfect health/death). Since the implementation
of this study, a debate has arisen as to whether utilities
anchored at perfect vision/death are measuring thesame construct as those anchored at perfect health/
death, and therefore whether they are appropriate for
calculating QALYs used in cost-utility analyses [51].
Secondly, the use of non-parametric statistical methods
implies that patients’ circumstances, which might influ-
ence individual perceptions of sight loss as a disability,
were not controlled for. However, univariable analyses
showed that none of the socio-demographic and clinical
characteristics were likely to confound the observed
associations. Furthermore, recruitment from one single
London-based hospital potentially limits the generalis-
ability of findings. Finally, comparisons with other studies
are hindered by the lack of an agreed system of glaucoma
staging.Conclusions
This study demonstrates that POAG reduces visual func-
tioning (VFL, VA) and vision-related QOL (VFQ-25
scores), affecting the 3 UVs to different extents: those
from TTO were the most sensitive, followed by SF-6D
and then EQ-5D, which was mostly unaffected. In gen-
eral, TTO utilities were highest in value and had the
strongest relationship with IVF, VAB (known-group dif-
ferences) and the VFQ-25 composite score (convergent
validity), implying higher overall sensitivity to glaucoma-
induced QOL changes.
Although TTO UVs correlated with glaucoma-induced
QOL changes better than those from SF-6D and EQ-5D,
our results do not go as far as to suggest that TTO’s sen-
sitivity is sufficiently adequate for POAG. In fact, none
of the generic instruments analysed appeared very sensi-
tive to differences in VFL or perceived visual function
for patients at milder stages of visual impairment. The
correlations of TTO UVs with ophthalmic and function-
ality measures may thus be mainly driven by their drop
among patients with end-stage POAG. Preferences may
be genuinely unchanged early on, elicitation methods
may be inadequate, or both. As several dimensions of
visual functioning were demonstrably affected from the
earlier stages, these UV elicitation methods are very
likely inadequate. This finding is crucial for the timing
of treatment against degenerative conditions such as
POAG, as cost-utility analysis should employ valid utility
measures that can detect genuine changes in preferences
over different stages. Underestimation of QALYs gained
by patients undergoing interventions to slow POAG pro-
gression might lead to delays in starting beneficial ther-
apies, which can cause unnecessary utility losses.
Although the use of TTO adapted for vision should be
encouraged over other generic QOL tools, economic
studies should question the validity of standard mea-
sures and identify, develop or validate in practice better
methods where necessary.
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